Intervention

3BNC117-LS

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 7 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials7

Recruiting0

Common conditions3

Lead sponsors shown3

Clinical trials

7 shown

bNAbs and Anti-PD-1 in HIVNCT07820813 · 2026-09-15

NOT_YET_RECRUITING

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATINCT05079451 · 2024-01-01

WITHDRAWN

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral TherapyNCT05612178 · 2023-07-26

ACTIVE_NOT_RECRUITING

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)NCT05245292 · 2022-12-07

COMPLETED

3BNC117-LS and 10-1074-LS in Viremic HIV-infected IndividualsNCT04250636 · 2020-10-13

COMPLETED

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LSNCT03554408 · 2018-06-20

COMPLETED

3BNC117-LS First-in-Human Phase 1 StudyNCT03254277 · 2017-09-13

COMPLETED

Common conditions

Human Immunodeficiency Virus4 HIV-12 HIV Infections1

Leading sponsors

Rockefeller University 4 National Institute of Allergy and Infectious Diseases (NIAID) 2 Ole Schmeltz Søgaard 1

Trial status mix

COMPLETED4

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

WITHDRAWN1

Phase mix

PHASE16

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.